The initial public offering (IPO) of Anthem Biosciences has opened for subscription and is attracting keen interest from both retail and institutional investors. As a leading contract research and manufacturing services (CRAMS) company based in India, Anthem Biosciences is tapping the public markets to raise capital for expansion and strategic investments.
The IPO comprises a fresh issue of equity shares along with an offer for sale (OFS) by existing shareholders. The company plans to use the proceeds from the fresh issue to invest in its research and development infrastructure, scale up manufacturing capacity, and reduce outstanding borrowings. The offer for sale is expected to provide partial exits to early investors and promoters.
Price Band and Lot Size
The price band for the Anthem Biosciences IPO has been fixed in the range of Rs 445 to Rs 468 per equity share. The minimum lot size for retail investors is set at 30 shares, which means that a single retail application would require an investment of at least Rs 14,040 at the upper price band. The IPO will remain open for subscription for three days.
Key Dates
- IPO Open Date: July 15
- IPO Close Date: July 17
Allotment Date: July 22
- Refunds Initiated: July 23
- Shares Credited to Demat Accounts: July 24
- Listing Date (Tentative): July 25
Grey Market Premium (GMP)
Market observers have noted that the IPO is trading at a grey market premium (GMP) of around Rs 85 to Rs 90 over the issue price, suggesting positive sentiment among investors. While GMP is unofficial and subject to market speculation, it is often seen as an early indicator of listing performance.
Company Profile
Anthem Biosciences, established in 2007, provides contract research and manufacturing services across pharmaceuticals, biotechnology, and life sciences. The company has grown rapidly in recent years and is recognised for its work in developing active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. With a strong domestic and international client base, the firm is positioned as a key player in the CRAMS industry.
The company operates major R&D and manufacturing facilities in Bengaluru and has steadily increased its capacity to meet global demand. Its integrated approach to research, development, and production gives it a competitive edge in the biopharma outsourcing space.
Investor Outlook
Given the company’s growth prospects, presence in a high-potential sector, and current demand in the grey market, analysts have expressed a largely positive outlook on the IPO. However, investors are also advised to consider risk factors such as industry competition, regulatory dependencies, and market volatility before subscribing.
As the subscription window progresses, investor participation will be closely monitored. The IPO's performance upon listing will serve as an indicator of market sentiment towards the biotech sector and upcoming public issues.
